Markets:

Overview

News

Currencies

International

Treasuries

RAPT Therapeutics, Inc. - Common Stock (NQ:RAPT)

58.02 UNCHANGED

Last Price Updated: 4:00 PM EST, Mar 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about RAPT Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

RAPT Therapeutics: Q4 Earnings Insights ↗

March 10, 2022

RAPT Therapeutics (NASDAQ:RAPT) reported its Q4 earnings results on Thursday, March 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement....

Via Benzinga

65 Biggest Movers From Yesterday ↗

January 19, 2022

Gainers Brickell Biotech, Inc. (NASDAQ: BBI) shares jumped 58.6% to settle at $0.33 on Tuesday after HC Wainwright & Co initiated coverage on the stock with a Buy rating and...

Via Benzinga

Why RAPT Therapeutics Stock Is Surging Today ↗

June 14, 2021

RAPT Therapeutics Inc (NASDAQ:RAPT) shares are tradin...

Via Benzinga

60 Biggest Movers From Yesterday ↗

January 11, 2022

Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ: ZNGA) rose 40.7% to settle at $8.44 after the company...

Via Benzinga

The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering ↗

November 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...

Via Benzinga

Topics Retirement

Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021 ↗

December 09, 2021

Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:

Via Benzinga

How Good Are RAPT Therapeutics's Earnings? | Return On Capital Employed ↗

September 28, 2021

According to Benzinga Pro data, during Q2, RAPT Therapeutics (NASDAQ:RAPT) posted sales of $869.00 thousand. Earnings were up 2.9%, but RAPT Therapeutics still reported an overall...

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug ↗

September 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2021 ↗

August 12, 2021

Upgrades According to Northland Capital Markets, the prior rating for Points International Ltd

Via Benzinga

10 Biggest Price Target Changes For Wednesday ↗

June 23, 2021

Wedbush boosted Microsoft Corporation (NASDAQ: MSFT) price target from $310 to $325. Microsoft shares slipped 0.1% to $265.48 in pre-market trading. Morgan Stanley boosted...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2021 ↗

June 21, 2021

Upgrades B of A Securities upgraded the previous rating for Cimarex Energy Co (NYSE:

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 21, 2021

Gainers MediciNova (NASDAQ:MNOV) shares moved upwards by 50.79% to $5.67 during Monday's pre-market session. The market value of their outstanding shares is at $276.5...

Via Benzinga

The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO ↗

June 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

June 16, 2021

Gainers Kindred Biosciences (NASDAQ:KIN) shares moved upwards by 45.26% to $9.21 during Wednesday's pre-market session. The market value of their outstanding shares is...

Via Benzinga

RAPT Therapeutics Raises $125M Via Equity At 6% Discount ↗

June 16, 2021

RAPT Therapeutics Inc (NASDAQ: RAPT) has priced its previously announced underwritten public offering of 3.8 million shares at $33/share. The price represents a 6...

Via Benzinga

Stocks That Hit 52-Week Highs On Tuesday ↗

June 15, 2021

Before 10 a.m. ET on Tuesday, 125 stocks hit new 52-week highs. Significant Points: The largest company by market cap to set a new 52-week high was Alphabet (NASDAQ...

Via Benzinga

The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda ↗

June 15, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14) Alkermes plc (NASDAQ: ALKS...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

June 14, 2021

Gainers RAPT Therapeutics (NASDAQ:RAPT) s...

Via Benzinga

Mid-Afternoon Market Update: Dow Tumbles 250 Points; Enochian Biosciences Shares Spike Higher ↗

June 14, 2021

Toward the end of trading Monday, the Dow traded down 0.74% to 34,225.89 while the NASDAQ rose 0.45% to 14,132.55. The S&P also fell, dropping 0.27% to 4,236.03. The U.S. has...

Via Benzinga

Topics Stocks

60 Biggest Movers From Yesterday ↗

June 15, 2021

Gainers RAPT Therapeutics, Inc. (NASDAQ: RAPT) shares jumped 115.5% to settle at $40.02 on Monday as the company announced topline results from its Phase 1b trial of RPT193 as...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 14, 2021

Gainers RAPT Therapeutics (NASDAQ:RAPT) shares moved upwards by 111.41% to $39.26 during Monday's regular session. As of 12:30 EST, this security is trading at a...

Via Benzinga

Why RAPT Therapeutics Stock Is Crushing It Today ↗

June 14, 2021

The company reported great results from an early-stage study of its experimental atopic dermatitis drug.

Via The Motley Fool

RAPT Stock: The Big Study News That Has RAPT Therapeutics Rocketing 100%+ ↗

June 14, 2021

RAPT Therapeutics (RAPT) stock is rocketing higher on Monday thanks to positive results from a recent clinical trial of RPT193.

Via InvestorPlace

Mid-Day Market Update: Nasdaq Rises Over 50 Points; Washington Prime Group Shares Plunge ↗

June 14, 2021

Midway through trading Monday, the Dow traded down 0.65% to 34,255.66 while the NASDAQ rose 0.41% to 14,126.79. The S&P also fell, dropping 0.23% to 4,237.53. The U.S. has the...

Via Benzinga

Topics Stocks

40 Stocks Moving In Monday's Mid-Day Session ↗

June 14, 2021

Gainers Enochian Biosciences, Inc. (NASDAQ: ENOB) shares jumped 127.2% to $10.02. The FDA has accepted Enochian BioSciences Inc's pre-IND (Investigational New Drug) request...

Via Benzinga

Mid-Morning Market Update: Markets Mostly Lower; Accenture To Acquire German Engineering Company ↗

June 14, 2021

Following the market opening Monday, the Dow traded down 0.43% to 34,332.41 while the NASDAQ rose 0.24% to 14,102.61. The S&P also fell, dropping 0.20% to 4,238.80. The U.S....

Via Benzinga

Topics Stocks

RAPT Therapeutics Stock Soars As Atopic Dermatitis Candidate Shows Promising Action In Early-Stage Study ↗

June 14, 2021

RAPT Therapeutics Inc (NASDAQ: RAPT) has announced topline results from its Phase 1b trial of RPT193 as monotherapy for moderate-to-severe atopic dermatitis (AD)....

Via Benzinga

48 Biggest Movers From Friday ↗

May 24, 2021

Gainers Annovis Bio, Inc. (NASDAQ: ANVS) shares surged 127.3% to close at $60.00 on Friday after the company announced new results from a Phase 2 study evaluating its lead drug...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.